Vitreous floaters – etiology, diagnostics and treatment Review article

Main Article Content

Joanna Skowronek
Anna Święch


Vitreous floaters are one of the most common complain of ophthalmological patients. The aetiology of floaters includes pathological process (vitreous haemorrhages, injuries, diabetics or uveitis) and also natural age-related changes in vitreous body. Diagnosis and treatment depends on the severity of the symptoms. Process of posterior vitreous detachment requires particularly careful monitoring, because of potential complications such as retinal tears or retinal detachment. Supplementation with anti-glycation and antioxidant substances allows to reduce complains of patients with vitreous floaters.


Download data is not yet available.

Article Details

How to Cite
Skowronek J, Święch A. Vitreous floaters – etiology, diagnostics and treatment. Ophthatherapy [Internet]. 2023Jun.30 [cited 2023Sep.24];10(2):103-8. Available from:
Conservative treatment


1. Webb BF, Jadon R, Schroeder MC et al. Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol. 2013; 6(3): 402-5.
2. Jamrozy-Witkowska A, Łukasik U, Skonieczna K et al. Zmiany w ciele szklistym związane z wiekiem – patogeneza, objawy i leczenie. Okulistyka. 2015; 1: 11-3.
3. de Smet MD, Gad Elkareem AM, Zwinderman AH. The Vitreous, the Retinal Interface in Ocular Health and Disease. Ophthalmologica. 2013; 230: 165-78.
4. Kim J, Lee HJ, Park IW et al. Comparison of Floaters after Cataract Surgery with Different Viscoelastics. Int J Med Sci. 2018; 15(3): 223-7.
5. Ankamah E, Sebag J, Ng E et al. Vitreous antioxidants, degeneration, and vitreo-retinopathy: exploring the links. Antioxidants. 2020; 9: 7.
6. Kamińska A, Dudek A. Rola ciała szklistego w procesie widzenia. Okulistyka. 2019; 3(XXII): 48-51.
7. Ankamah E, Green-Gomez M, Roche W et al. Dietary Intervention With a Targeted Micronutrient Formulation Reduces the Visual Discomfort Associated With Vitreous Degeneration. Transl Vis Sci Technol. 2021; 10(12): 19.
8. Deguine V, Menasche M, Ferrari P et al. Free radical depolymerization of hyaluronan by Maillard reaction products: role in liquefaction of aging vitreous. Int J Biol Macromol. 1998; 22: 17-22.
9. Deguine V, Labat-Robert J, Ferrari P et al. Aging of the vitreous body. Role of glycation and free radicals. Pathol Biol (Paris). 1997; 45: 321-30.
10. Sulochana KN, Ramprasad S, Coral K et al. Glycation and glycoxidation studies in vitro on isolated human vitreous collagen. Med Sci Monit. 2003; 9(6): BR260-4.
11. Sobol M, Oseka M, Kaercher Th et al. (BON 030) The effect of oral supplementation with L-lysine, hesperidin, proanthocyanidins, vitamin C and zinc on the subjective assessment of the quality of vision in patients with vitreous floaters. J Alzheimers Dis. 2018; 3(64): 1034.
12. Raczyńska K, Kokot W, Krajka-Lauer J et al. Jod w leczeniu zwyrodnienia ciała szklistego. Klin Oczna. 2004; 3(Suplement): 518-20.
13. Winkler R. Iodine – A Potential Antioxidant and the Role of Iodine/Iodide in Health and Disease. Nat Sci. 2015; 7: 548-57.
14. Broadhead GK, Hong T, Chang AA. To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters. Asia Pac J Ophthalmol (Phila). 2020; 9(2): 96-103.
15. Souza CE, Lima LH, Nascimento H et al. Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters. Int J Retina Vitreous. 2020; 6: 1.
16. Brasse K, Schitz-Valckenberg S, Junemann A et al. YAG laser vitreolysis for treatment of symptomatic vitreous opacities. Ophthalmologe. 2019; 116(1): 73-84.
17. Sobolewski P. Witreoliza i zwyrodnienie ciała szklistego – zapobieganie, leczenie i rozpoznawanie. Okulistyka po Dyplomie. 2015; 1: 11-3.
18. Milston R, Madigan MC, Sebag J. Vitreous floaters: Etiology, diagnostics, and management. Surv Ophthalmol. 2016; 61(2): 211-27.
19. Mason JO 3rd, Neimkin MG, Mason JU 4th et al. Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters. Retina. 2014; 34(6): 1055-61.
20. Wagle AM, Lim W-Y, Yap T-P et al. Utility values associated with vitreous floaters. Am J Ophthalmol. 2011; 152(1): 60-5.
21. Sebag J. Floaters and the quality of life. Am J Ophthalmol. 2011; 152(1): 3-4.e1.
22. Kim Y-K, Young Moon S, Mi Yim K. Psychological Distress in Patients with Symptomatic Vitreous Floaters. J Ophthalmol. 2017; 2017: 3191576.